中医药调节结直肠癌免疫微环境的研究进展
Research progress of traditional Chinese medicine regulating immune microenvironment of colorectal cancer
- 上海中医药大学学报 2021年35卷第4期 页码：94-100
- 作者机构：
1.上海中医药大学附属龙华医院，上海中医药大学脾胃病研究所（上海 200032）
- 作者简介：
钱雨凡，女，在读硕士生，主要从事中医药治疗消化系统肿瘤的基础研究
徐汉辰，副研究员，硕士生导师；E-mail：hanson0702@126.com
- 基金信息：上海市科委青年科技启明星计划项目(20QA1409300);上海高校青年东方学者岗位计划资助项目
DOI：10.16306/j.1008-861x.2021.04.014
中图分类号：
扫 描 看 全 文
钱雨凡, 刘宇婧, 陆璐, 等. 中医药调节结直肠癌免疫微环境的研究进展[J]. 上海中医药大学学报, 2021,35(4):94-100.
QIAN Yufan, LIU Yujing, LU Lu, et al. Research progress of traditional Chinese medicine regulating immune microenvironment of colorectal cancer[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2021,35(4):94-100.
钱雨凡, 刘宇婧, 陆璐, 等. 中医药调节结直肠癌免疫微环境的研究进展[J]. 上海中医药大学学报, 2021,35(4):94-100. DOI： 10.16306/j.1008-861x.2021.04.014.
QIAN Yufan, LIU Yujing, LU Lu, et al. Research progress of traditional Chinese medicine regulating immune microenvironment of colorectal cancer[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2021,35(4):94-100. DOI： 10.16306/j.1008-861x.2021.04.014.
摘要
结直肠癌是临床常见的恶性肿瘤，目前治疗方式主要包括手术、放疗、化疗及靶向治疗，随着免疫检查点抑制剂的临床应用，结直肠癌进入了免疫治疗时代。中医药作为肿瘤综合治疗的一部分，在结直肠癌的治疗中运用广泛。中医药对结直肠癌免疫微环境的调节是其发挥治疗作用的主要途径之一，主要表现在调节T细胞介导的适应性免疫及固有免疫细胞介导的免疫反应。从免疫微环境对结直肠癌发生发展的影响、中医药调节结直肠癌免疫微环境等方面进行综述，以期为中医药参与的肿瘤免疫治疗研究提供思路。
Abstract
Colorectal cancer is a common malignant tumor in clinic.At present, the treatment methods mainly include surgery, radiotherapy, chemotherapy and targeted therapy.With the clinical application of immune checkpoint inhibitors, the therapy for colorectal cancer has entered the era of immunotherapy.As a part of comprehensive treatment on cancer, traditional Chinese medicine is widely used in the treatment of colorectal cancer.The regulation of traditional Chinese medicine on the immune microenvironment of colorectal cancer is one of the main ways to play its therapeutic role, which mainly manifests in the regulation of adaptive immunity mediated by T cells and immune response mediated by innate immune cells.This paper reviews the influence of immune microenvironment on the occurrence and development of colorectal cancer, as well as the regulation of traditional Chinese medicine on the immune microenvironment of colorectal cancer, so as to provide ideas for the research of tumor immunotherapy with traditional Chinese medicine.
关键词
结直肠癌免疫微环境中医药综述
Keywords
colorectal cancerimmune microenvironmenttraditional Chinese medicinereview
references
OGINO S，CHAN A T，FUCHS C S，et al.Molecular pathological epidemiology of colorectal neoplasia：an emerging transdisciplinary and interdisciplinary field[J]. Gut，2011，60(3)：397-411.
SUNG H，FERLAY J，SIEGEL R L，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
GUINNEY J，DIENSTMANN R，WANG X，et al. The consensus molecular subtypes of colorectal cancer[J]. Nat Med，2015，21(11)：1350-1356.
赵彪，杜欣颖.中医在大肠癌整合治疗中的应用[J].医学争鸣，2021，12(1)：18-23.
杨宇飞.中医药在结直肠癌治疗中的优势与展望[J].中国中西医结合杂志，2020，40(11)：1294-1297.
任明名，王俊壹，程海波.中医药与肿瘤免疫治疗[J].自然杂志，2019，41(4)：45-50.
郭飘婷，王松坡.历代中医论治大肠癌[J].吉林中医药，2016，36(3)：223-227.
YATIM K M，LAKKIS F G. A brief journey through the immune system[J]. Clin J Am Soc Nephrol，2015，10(7)：1274-1281.
NICHOLSON L B.The immune system[J]. Essays Biochem，2016，60(3)：275-301.
BINNEWIES M，ROBERTS E W，KERSTEN K，et al. Understanding the tumor immune microenvironment（TIME）for effective therapy[J]. Nat Med，2018，24(5)：541-550.
TAUBE J M，GALON J，SHOLL L M，et al. Implications of the tumor immune microenvironment for staging and therapeutics[J]. Mod Pathol，2018，31(2)：214-234.
GAJEWSKI T F，SCHREIBER H，FU Y X. Innate and adaptive immune cells in the tumor microenvironment[J]. Nat Immunol，2013，14(10)：1014-1022.
CASSIM S，POUYSSEGUR J.Tumor microenvironment：A metabolic player that shapes the immune response[J]. Int J Mol Sci，2019，21(1)：157.
JOHDI N A，AIT-TAHAR K，SAGAP I，et al.Molecular signatures of human regulatory T cells in colorectal cancer and polyps[J]. Front Immunol，2017，8：620.
KAZAMA K，OTAKE J，SATOYOSHI T，et al. Distribution of regulatory T-cells and other phenotypes of T-cells in tumors and regional lymph nodes of colorectal cancer patients[J]. In Vivo，2020，34(2)：849-856.
MITEVA L D，STANILOV N S，CIROVSKI G М，et al.Upregulation of Treg-related genes in addition with IL6 showed the significant role for the distant metastasis in colorectal cancer[J]. Cancer Microenviron，2017，10(1-3)：69-76.
BINNEWIES M，MUJAL A M，POLLACK J L，et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity[J]. Cell，2019，177(3)：556-571.
SPITZER M H，CARMI Y，RETICKER-FLYNN N E，et al.Systemic immunity is required for effective cancer immunotherapy[J]. Cell，2017，168(3)：487-502.
LI Z H，LI S Y，LIANG Y，et al.Predictive value of postoperative peripheral CD4+ T cells percentage in stage Ⅰ-Ⅲ colorectal cancer：A retrospective multicenter cohort study of 1028 subjects[J]. Cancer Manag Res，2020，12：5505-5513.
ZUAZO M，ARASANZ H，FERNÁNDEZ-HINOJAL G，et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy[J]. EMBO Mol Med，2019，11(7)：e10293.
MORISHIMA N，OWAKI T，ASAKAWA M，et al.Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27[J]. J Immunol，2005，175(3)：1686-1693.
NAITO Y，SAITO K，SHIIBA K，et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer[J]. Cancer Res，1998，58(16)：3491-3494.
GALON J，COSTES A，SANCHEZ-CABO F，et al.Type，density，and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science，2006，313(5795)：1960-1964.
JANG T J.Progressive increase of regulatory T cells and decrease of CD8+ T cells and CD8+ T cells/regulatory T cells ratio during colorectal cancer development[J]. Korean J Pathol，2013，47(5)：443-451.
WANG B，LI F，GUO L，et al. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+ T cell[J]. World J Surg Oncol，2020，18(1)：196.
FRANCISCO L M，SAGE P T，SHARPE A H.The PD-1 pathway in tolerance and autoimmunity[J]. Immunol Rev，2010，236：219-242.
NOMI T，SHO M，AKAHORI T，et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer[J]. Clin Cancer Res，2007，13(7)：2151-2157.
THOMPSON R H，GILLETT M D，CHEVILLE J C，et al. Costimulatory B7-H1 in renal cell carcinoma patients：Indicator of tumor aggressiveness and potential therapeutic target[J]. Proc Natl Acad Sci U S A，2004，101(49)：17174-17179.
BERNTSSON J，EBERHARD J，NODIN B，et al. Expression of programmed cell death protein 1（PD-1）and its ligand PD-L1 in colorectal cancer：Relationship with sidedness and prognosis[J]. Oncoimmunology，2018，7(8)：e1465165.
OVERMAN M J，MCDERMOTT R，LEACH J L，et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142）：an open-label，multicentre，phase 2 study[J]. Lancet Oncol，2017，18(9)：1182-1191.
LE D T，URAM J N，WANG H，et al.PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med，2015，372(26)：2509-2520.
SASIDHARAN NAIR V，TOOR S M，TAHA R Z，et al. DNA methylation and repressive histones in the promoters of PD-1，CTLA-4，TIM-3，LAG-3，TIGIT，PD-L1，and galectin-9 genes in human colorectal cancer[J]. Clin Epigenetics，2018，10(1)：104.
CIARDIELLO D，VITIELLO P P，CARDONE C，et al. Immunotherapy of colorectal cancer：Challenges for therapeutic efficacy[J]. Cancer Treat Rev，2019，76：22-32.
SASIDHARAN NAIR V，TOOR S M，TAHA R Z，et al. Transcriptomic profiling of tumor-infiltrating CD4+ TIM-3+ T cells reveals their suppressive，exhausted，and metastatic characteristics in colorectal cancer patients[J]. Vaccines（Basel），2020，8(1)：71.
AVERY L，FILDERMAN J，SZYMCZAK-WORKMAN A L，et al. Tim-3 co-stimulation promotes short-lived effector T cells，restricts memory precursors，and is dispensable for T cell exhaustion[J]. Proc Natl Acad Sci U S A，2018，115(10)：2455-2460.
SYED KHAJA A S，TOOR S M，EL SALHAT H，et al.Intratumoral FoxP3+ Helios+ Regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer[J]. Front Immunol，2017，8：619.
TOOR S M，SYED KHAJA A S，EL SALHAT H，et al.Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients[J]. Front Immunol，2016，7：560.
ZHANG L H，ZHAO Y T，DAI Y，et al. Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location[J]. Front Immunol，2018，9：1578.
MITA Y，KIMURA M Y，HAYASHIZAKI K，et al.Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells[J]. Int Immunol，2018，30：559-567.
SAITO T，NISHIKAWA H，WADA H，et al.Two FOXP3+ CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers[J]. Nat Med，2016，22(6)：679-684.
LADOIRE S，MARTIN F，GHIRINGHELLI F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas：the paradox of colorectal cancer[J]. Cancer Immunol Immunother，2011，60(7)：909-918.
TERRÉN I，ORRANTIA A，VITALLÉ J，et al.NK cell metabolism and tumor microenvironment[J]. Front Immunol，2019，10：2278.
OPPENHEIM D E，SPREAFICO R，ETUK A，et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy[J]. Br J Cancer，2014，110(5)：1221-1227.
VELUCHAMY J P，LOPEZ-LASTRA S，SPANHOLTZ J，et al.In vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer[J]. Front Immunol，2017，8：87.
TANG S W，FU H Y，XU Q H，et al.MiR-20a regulates sensitivity of colorectal cancer cells to NK cells by targeting MICA[J]. Biosci Rep，2019，39(7)：BSR20180695.
ROCCA Y S，ROBERTI M P，JULIÁ E P，et al.Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15[J]. Front Immunol，2016，7：413.
ROCCA Y S，ROBERTI M P，ARRIAGA J M，et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients[J]. Innate Immun，2013，19(1)：76-85.
CAVNAR M J，TURCOTTE S，KATZ S C，et al.Tumor-associated macrophage infiltration in colorectal cancer liver metastases is associated with better outcome[J]. Ann Surg Oncol，2017，24(7)：1835-1842.
FUNES S C，RIOS M，ESCOBAR-VERA J，et al.Implications of macrophage polarization in autoimmunity[J]. Immunology，2018，154(2)：186-195.
ZHANG R S，QI F，ZHAO F，et al.Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer[J]. Cell Death Dis，2019，10(4)：273.
LIANG Z X，LIU H S，WANG F W，et al. Correction：LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization[J]. Cell Death Dis，2020，11(6)：465.
ZHAO S L，MI Y S，GUAN B J，et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer[J]. J Hematol Oncol，2020，13(1)：156.
ZHANG Y，LUO Y，QIN S L，et al.The clinical impact of ICOS signal in colorectal cancer patients[J]. Oncoimmunology，2016，5(5)：e1141857.
WANG C Y，DING H Z，TANG X，et al.Comparative analysis of immune function，hemorheological alterations and prognosis in colorectal cancer patients with different traditional Chinese medicine syndromes[J]. Cancer Biomark，2018，21(3)：701-710.
崔巍，刘飒，杨敏，等.熊胆粉联合环磷酰胺用药通过调控肿瘤微环境抑制结直肠癌肝转移作用的研究[J].中国中药杂志，2013，38(7)：1036-1040.
XU H，VAN DER JEUGHT K，ZHOU Z，et al.Atractylenolide Ⅰ enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation[J]. J Clin Invest，2021，131(10)：e146832.
LI Y，LI Z X，XIE C Y，et al.Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota[J]. World J Gastroenterol，2020，26(48)：7633-7651.
LV J，JIA Y T，LI J，et al.Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment[J]. Cell Death Dis，2019，10(6)：415.
顾国群，范耀华.补气益肾方联合化疗治疗结直肠癌的近期疗效及对患者免疫功能、肿瘤标志物的影响[J].中国基层医药，2020，27(4)：471-474.
王浩咏，刘国荣.参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响[J].中国当代医药，2020，27(9)：78-80,84.
HUANG S Q，PENG W J，MAO D，et al. Kangai Injection，a traditional Chinese medicine，improves efficacy and reduces toxicity of chemotherapy in advanced colorectal cancer patients：A systematic review and meta-analysis[J]. Evid Based Complement Alternat Med，2019，2019：8423037.
XU R Z，LIN L B，LI Y，et al.ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer：A meta-analysis[J]. PLoS One，2017，12(9)：e0185254.
CHEN D，YANG Y F，YANG P Y.Quxie capsule inhibits colon tumor growth partially through Foxo1-mediated apoptosis and immune modulation[J]. Integr Cancer Ther，2019，18：1534735419846377.
陈力川，汪思亮，余苏云，等.NK细胞在肿瘤免疫治疗中的研究进展[J].肿瘤，2017，31(1)：101-106.
崔澂，王润田，胡建军，等.抗肿瘤中药制剂逆转结直肠癌NK细胞免疫抑制的靶分子探讨[J].江苏医药，2011，37(5)：509-512.
CUI C，ZHANG A X，HU J J，et al.Reversing effects of traditional Chinese antitumor medicines on colorectal tumor immunosuppression of natural killer cell and T lymphocyte in vitro[J]. Chinese-German J Clin Oncol，2012，11(12)：721-731.
崔澂，李保红，王润田，等.不同类别抗瘤中药制剂逆转结直肠癌NK免疫功能抑制的比较研究[J].白求恩军医学院学报，2010，8(2)：86-88.
赵晓华，刘桂，温珍平.升血汤对转移性结直肠癌化疗所致骨髓抑制及免疫功能的影响[J].现代中西医结合杂志，2017，26(12)：1321-1323.
许炜茹，张青，富琦，等.升血汤对转移性结直肠癌化疗患者骨髓抑制及免疫功能的影响[J].中华中医药杂志，2015，30(6)：2230-2232.
莫淑婵，田甜，吴钟彪.升血汤对转移性结直肠癌化疗患者免疫 功能及相关性贫血的影响[J].中医药导报，2018，24(1)：70-72.
李莹莹.升血汤对转移性结直肠癌化疗患者免疫功能及相关性贫血的影响[J].内蒙古中医药，2018，37(8)：61-62.
崔澂，王润田，支国成，等.不同类别抗瘤中药制剂下调结直肠癌免疫功能抑制的比较研究[J].实用肿瘤杂志，2010，25(3)：300-304.
ZHOU J Y，CHEN M，WU C E，et al. The modified Si-Jun-Zi Decoction attenuates colon cancer liver metastasis by increasing macrophage cells[J]. BMC Complement Altern Med，2019，19(1)：86.
王海艳.复方肠泰诱导结肠癌细胞自噬活化巨噬细胞的研究[D].南京：南京中医药大学，2016.
王建华.复方肠泰诱导结肠癌细胞自噬促进肿瘤相关巨噬细胞极化的机制研究[D].南京：南京医科大学，2018.
陈纯辉.大黄蟅虫丸改善外泌体CCL2启动介导的转移前微环境抑制结直肠癌肝转移[D].广州：南方医科大学，2019.
SUI H，TAN H S，FU J，et al. The active fraction of Garcinia yunnanensis suppresses the progression of colorectal carcinoma by interfering with tumor associated macrophage-associated M2 macrophage polarization in vivo and in vitro[J]. FASEB J，2020，34(6)：7387-7403.
0
浏览量
905
下载量
0
CSCD
14
CNKI被引量
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：10152 今日访问量：15